AVIR

SEC source: 0000950170-25-013846 · ownership.xml · nonDerivative · entry 1

Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 6

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-01-30

F6 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.

SEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 5

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 10,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

F5 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 4

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,366

Underlying: Common Stock · 44,367 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F4 · derivative.expiration_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

SEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 3

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 717,307

SEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 733,409

F3 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").

SEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 722,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 8,334 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

SEC source: 0000950170-25-013853 · ownership.xml · derivative · entry 6

Hammond Janet MJ · CIK 0001829899 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-01-30

F6 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.

SEC source: 0000950170-25-013853 · ownership.xml · derivative · entry 5

Hammond Janet MJ · CIK 0001829899 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

F5 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0000950170-25-013853 · ownership.xml · derivative · entry 4

Hammond Janet MJ · CIK 0001829899 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,800

Underlying: Common Stock · 46,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The original grant of 140,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F4 · derivative.expiration_date: The original grant of 140,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

SEC source: 0000950170-25-013853 · ownership.xml · nonDerivative · entry 3

Hammond Janet MJ · CIK 0001829899 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,388

SEC source: 0000950170-25-013853 · ownership.xml · nonDerivative · entry 2

Hammond Janet MJ · CIK 0001829899 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,522

F3 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").

SEC source: 0000950170-25-013853 · ownership.xml · nonDerivative · entry 1

Hammond Janet MJ · CIK 0001829899 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 2,110 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

SEC source: 0000950170-25-013852 · ownership.xml · derivative · entry 7

Vavricka John · CIK 0001829630 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,800

Underlying: Common Stock · 132,800 shares

Expires 2035-01-30

F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.

SEC source: 0000950170-25-013852 · ownership.xml · derivative · entry 6

Vavricka John · CIK 0001829630 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,750

Underlying: Common Stock · 8,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0000950170-25-013852 · ownership.xml · derivative · entry 5

Vavricka John · CIK 0001829630 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F3 · derivative.expiration_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

SEC source: 0000950170-25-013852 · ownership.xml · nonDerivative · entry 3

Vavricka John · CIK 0001829630 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,081

SEC source: 0000950170-25-013852 · ownership.xml · nonDerivative · entry 2

Vavricka John · CIK 0001829630 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,598

F2 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").

SEC source: 0000950170-25-013852 · ownership.xml · nonDerivative · entry 1

Vavricka John · CIK 0001829630 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-013850 · ownership.xml · derivative · entry 6

Horga Maria Arantxa · CIK 0001829614 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,800

Underlying: Common Stock · 192,800 shares

Expires 2035-01-30

F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.

SEC source: 0000950170-25-013850 · ownership.xml · derivative · entry 5

Horga Maria Arantxa · CIK 0001829614 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,750

Underlying: Common Stock · 9,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0000950170-25-013850 · ownership.xml · derivative · entry 4

Horga Maria Arantxa · CIK 0001829614 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,533

Underlying: Common Stock · 41,533 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The original grant of 124,600 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F3 · derivative.expiration_date: The original grant of 124,600 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

SEC source: 0000950170-25-013850 · ownership.xml · nonDerivative · entry 3

Horga Maria Arantxa · CIK 0001829614 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,876

SEC source: 0000950170-25-013850 · ownership.xml · nonDerivative · entry 2

Horga Maria Arantxa · CIK 0001829614 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,947

F2 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").

SEC source: 0000950170-25-013850 · ownership.xml · nonDerivative · entry 1

Horga Maria Arantxa · CIK 0001829614 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,197

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-006589 · ownership.xml · nonDerivative · entry 2

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 476,897

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F1 · acquired: This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error.

SEC source: 0000950170-25-006489 · ownership.xml · nonDerivative · entry 2

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 476,897

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-006589 · ownership.xml · nonDerivative · entry 1

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 466,897

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F1 · acquired: This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error.

SEC source: 0000950170-25-006489 · ownership.xml · nonDerivative · entry 1

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 466,897

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-135930 · ownership.xml · nonDerivative · entry 1

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 451,897

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.955. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-108233 · ownership.xml · nonDerivative · entry 3

Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman

10b5-1 filing: Plan reported

Ownership: Indirect · Held by JPM Partners LLC

Disclosed balance after: 5,866,025

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-108233 · ownership.xml · nonDerivative · entry 2

Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman

10b5-1 filing: Plan reported

Ownership: Indirect · Held by JPM Partners LLC

Disclosed balance after: 5,867,866

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-108233 · ownership.xml · nonDerivative · entry 1

Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman

10b5-1 filing: Plan reported

Ownership: Indirect · Held by JPM Partners LLC

Disclosed balance after: 5,890,053

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-076388 · ownership.xml · derivative · entry 2

Adams Jerome M. · CIK 0001863366 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-24-076388 · ownership.xml · derivative · entry 1

Adams Jerome M. · CIK 0001863366 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-076379 · ownership.xml · derivative · entry 3

Polsky Bruce · CIK 0001508458 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-24-076379 · ownership.xml · derivative · entry 2

Polsky Bruce · CIK 0001508458 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F3 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-076400 · ownership.xml · derivative · entry 2

Duncan Barbara Gayle · CIK 0001353128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-24-076400 · ownership.xml · derivative · entry 1

Duncan Barbara Gayle · CIK 0001353128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-076394 · ownership.xml · derivative · entry 2

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-24-076394 · ownership.xml · derivative · entry 1

BERGER FRANKLIN M · CIK 0001273885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-076381 · ownership.xml · derivative · entry 2

Lucidi Bruno · CIK 0001829622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-24-076381 · ownership.xml · derivative · entry 1

Lucidi Bruno · CIK 0001829622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-076363 · ownership.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0000950170-24-076363 · ownership.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000950170-24-076379 · ownership.xml · nonDerivative · entry 1

Polsky Bruce · CIK 0001508458 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,606

F1 · price: The shares were sold solely to cover taxes upon the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.53, inclusive.

SEC source: 0000950170-24-074984 · ownership.xml · derivative · entry 2

Adams Jerome M. · CIK 0001863366 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units are fully vested.

F3 · derivative.expiration_date: The restricted stock units do not have an expiration date.

SEC source: 0000950170-24-074984 · ownership.xml · nonDerivative · entry 1

Adams Jerome M. · CIK 0001863366 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000950170-24-074986 · ownership.xml · derivative · entry 2

Polsky Bruce · CIK 0001508458 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units are fully vested.

F3 · derivative.expiration_date: The restricted stock units do not have an expiration date.

SEC source: 0000950170-24-074986 · ownership.xml · nonDerivative · entry 1

Polsky Bruce · CIK 0001508458 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.